Acute Ischemic Stroke – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Acute Ischemic Stroke Emerging Therapy and TPP Insights

Thelansis’s “Acute Ischemic Stroke Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acute Ischemic Stroke Overview

Acute ischemic stroke is a neurological emergency caused by sudden interruption of cerebral blood flow, most commonly from arterial occlusion, leading to rapid brain injury and potentially permanent disability. Acute care centers on restoring perfusion as quickly as possible through intravenous thrombolysis with alteplase or tenecteplase and endovascular thrombectomy for eligible patients. Recent advances have expanded treatment to selected patients with later presentation or larger ischemic cores, making patient selection increasingly dependent on advanced imaging and rapid triage. Yet reperfusion does not completely prevent secondary ischemic and reperfusion-related neuronal injury, leaving substantial interest in therapies that protect threatened brain tissue. Development is therefore extending beyond recanalization toward improved thrombolytics, neuroprotective strategies, immunomodulation, and early-stage regenerative therapies. Tenecteplase already represents an important evolution in thrombolysis, with FDA approval for AIS and guideline-supported use alongside alteplase. For stakeholders, AIS illustrates how innovation is shifting from simply reopening blocked vessels toward extending eligibility, protecting vulnerable tissue, and improving recovery after reperfusion.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)